Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome - 05/12/24
Doi : 10.1016/j.jaad.2024.10.095
Omar Elghawy, MD a, Austin G. Yang, BA a, Jonathan H. Sussman, BS a, Colin J. Thomas, MD a, Jordan S. Carter, MD a, Daniel J. Landsburg, MD a, Jakub Svoboda, MD a, Ellen Kim, MD b, Alain H. Rook, MD b, Jina Chung, MD b, Jennifer Villasenor-Park, MD, PhD b, John P. Plastaras, MD c, Michael LaRiviere, MD c, Harper Hubbeling, MD c, Monica Chelius, MD c, Sunita D. Nasta, MD a, Elise A. Chong, MD a, Stephen J. Schuster, MD a, Stefan K. Barta, MD, MS a, ⁎ 
a Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
b Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
c Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
∗Correspondence to: Stefan K. Barta, MD, MS, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, West Pavilion, 3400 Civic Center Blvd 2nd Floor, Philadelphia, PA 19104-4283Lymphoma ProgramAbramson Cancer CenterUniversity of PennsylvaniaWest Pavilion3400 Civic Center Blvd 2nd FloorPhiladelphiaPA19104-4283
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Thursday 05 December 2024
Key words : drug response, duvelisib, lenalidomide, mycosis fungoides, oncology, Sézary syndrome, T-cell lymphoma
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Reviewed and deemed exempt by the University of Pennsylvania IRB (case 855926). |
|
| Preferred reviewers: NA. |
© 2024
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?